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1. Introduction 
Human serum contains 7 well characterized pro- 
teinase inhibitors with more or less broad specificity 
to serine proteinases [ 1,2]. In addition, two inhibitors 
not inhibiting serine proteinases have been described: 
fl,-collagenase inhibitor [3] and cYz-thiol proteinase 
inhibitor [4]. The partially purified cuz-thiol pro- 
teinase inhibitor has been shown not to be identical 
with the known inhibitors of serine proteinases. Its 
properties are also quite different from those of the 
human epidermal thiol proteinase inhibitor, purified 
in our laboratory [5,6]. 
Here I describe the purification of two thiol pro- 
teinase inhibitors with (ILL- and CQ-mobilities from 
human serum. The purified inhibitors resemble each 
other in their immunological properties and inhibiting 
spectra, but have different charges and molecular 
sizes. The inhibitor with cYz-mobility seems to be 
identical with the thiol proteinase inhibitor in [4]. A 
preliminary note of this work has been published [7]. 
2. Materials and methods 
Normal human serum was prepared from the 
blood of healthy donors. The serum samples of at 
least 8 donors were pooled. Papain (for biochemical 
purposes) was obtained from E. Merck., ficin (crude), 
bromelain (grade II), bovine trypsin (type III) and 
chymotrypsin (type II) and porcine elastase (type I) 
were obtained from Sigma Chemical Co. Cathepsin B 
was prepared from human liver by the method in [8] 
and the epidermal thiol proteinase inhibitor and its 
antiserum as in [9]. Ampholine@ carrier ampholytes 
Elsevier/North-Holland Biomedical Press 
were obtained from LKB. Rabbit antisera against 
human albumin, al-antitrypsin, crl-antichymotrypsin, 
ceruloplasmin and Gc-globulins were obtained from 
Dako, rabbit antisera against inter+trypsin inhib- 
itor, CQ-macroglobulin, antithrombin III, C1-inactivator, 
al-acid glycoprotein, cu*-HS-glycoprotein, hapto- 
globin, p1-C//31-A-globulins, a2-PA glycoprotein and 
cul-lipoprotein, and horse antiserum to whole human 
serum proteins were from Behringwerke. Papain- 
Sepharose 4B was prepared as in [9]. 
The inhibition of papain, ficin, bromelain, and 
cathepsin B was assayed using benzoylarginine-2- 
napthylamide, and inhibition of trypsin, chymo- 
trypsin, and elastase using azocasein as a substrate 
[5]. The inhibition was expressed as the amount of 
an enzyme (mg) inhibited by 1 mg inhibitor (U/mg), 
or by 1 ml inhibitor solution (U/ml). 
The protein concentrations were measured by the 
method in [IO]. Protein solutions were concentrated 
by ultrafiltration on a Diaflo@ UM-10 membrane 
(Amicon). 
Rabbits were immunized 4 times intradermally 
with the purified inhibitor preparation (0.05 mg/ml) 
by the procedure in [7]. Immunodiffusion, immuno- 
electrophoresis, analytical electrofocusing (Ampholine 
pH 3.5-10) and preparative electrofocusing in sucrose 
gradient (Ampholine pH 4-6) were performed as in 
151. 
2.1. Purijkation procedure 
AU procedures were done in a cold room (t4”C). 
1. Acid treatment. The serum was adjusted to 
pH 5.0 with 2 M HCl, the precipitated proteins 
were removed by centrifugation, and the super- 
natant was neutralized. The procedure removed 
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Fig.1. Papain-Sepharose affinity chromatography. At the 
points indicated by arrows, PBS (l), 4 M KSCN (2) and 
20 mM Na,PO,, 0.1 M NaCl (3) were applied. Flowrate 
was 60 ml/h, and fraction vol. 5.5 ml. Fractions no. 62273 
were pooled. 
some material that was harmful in the following 
step. 
2. Papain-Sepharose chromatography (fig.1). A 
2.6 X 11 cm column of papain-Sepharose 4B was 
equilibrated with 10 mM phosphate buffer (pH 
7.2) containing 0.145 M NaCl (phosphate- 
buffered saline, PBS). Acid-treated serum (60 ml) 
was applied to the column, unadsorbed proteins 
were washed out with PBS, unspecifically adsorbed 
proteins with 4 M KSCN dissolved in PBS, KSCN 
was washed out with PBS and the inhibitors were 
elutedwith20mM Na3P04,0.1 M NaCl(pH 12.1). 
2.3. DEAE-Sephacel chromatography (fig.21 
The pooled inhibitors from the preceding step 
were dialyzed against 20 mM Tris-HCl buffer, con- 
taining 50 mM NaCl, and applied to a 1.6 X 20 cm 
column of DEAE-Sephacel@ (Pharmacia Fine 
Chemicals), equilibrated with the same buffer. The 
inhibitors were eluted with a linear gradient of NaCl 
(50-500 mM, total vol. 500 ml). Two inhibitor 
peaks, preparations I and II were fractionated and 
pooled separately. 
2.4. Sephadex G-150 chromatography 
The inhibitor preparations I and II were further 
fractionated in a 2.6 X 90 cm column of Sephadex 
G-l 50 (Pharmacia Fine Chemicals), equilibrated 
with 20 mM Tris-HCl buffer (pH 7.2) containing 
50 mM NaCl. 
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Fig.2. DEAE-Sephacel chromatography. The flowrate was 
30 ml/h and the fraction vol. 5.5 ml. Inhibitor I (fractions 
no. 35-39) and inhibitor II (fractions no. 45-47) were 
pooled separately. 
3. Results 
The purification procedure is summarized in 
table 1. Inhibitor I was 268-fold and inhibitor II 
175-fold purified and the total inhibitor yield 12%, 
as compared to the activity of the acid-treated serum. 
The molecular weight of inhibitor I was - 90 000 
and that of inhibitor II - 175 000, as estimated by 
gel chromatography on Sephadex G-l 50. In prepara- 
tive isoelectric focusing inhibitor I was focused at 
pH 4.6-4.7. During the focusing the inhibitor lost 
- 80% of its activity. The inhibitor II was focused 
at the steep pH front at the acidic end of the gra- 
dient (at pH 3.2-3.5). The heterogenity of inhibitor 
I was studied by analytical isoelectric focusing. Two 
distinct anodal bands were seen after staining of the 
gels with Coomassie brilliant blue or with the peri- 
Table 1 
Summary of the purification procedure 




Acid-treated serum 60 4320 0.014 60.5 
Papain-Sepharose 82 7.79 3.05 23.8 
DEAE-Sephacel I 33 2.94 3.82 11.2 
II 17 1.06 2.50 2.7 
Sephadex G-150 I 37 1.48 3.75 5.6 
II 27 0.59 2.45 1.5 
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odic acid-Schiff procedure, suggesting that inhibitor 
I is a glycoprotein. 
Inhibitors I and II had the same specificity against 
proteinases (fig.3): they strongly inhibited papain 
and ficin, cathepsin B and bromelain less intensively, 2100 ?/ 
and did not inhibit trypsin, chymotrypsin and elastase 
at all. The results suggest hat the inhibitors are group- 
.$’ 
5 
specific to thiol proteinases. 
Fig.3. Inhibition of several thiol proteinases with the purified 
inhibitors I and II. Trypsin, chymotrypsin and elastase were 
not inhibited (not shown in the figure). 
December 1979 
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Fig. 4. Immunoelectrophoresis of the purified inhibitors. (1) 1.25 ~1 of human serum; (2) 0.9 ng Inhibitor I; (3) 10 ~1 human 
seru .m; (4) 0.9 clg inhibitor II; (5) 100 ~1 horse antiserum against human serum proteins; (6) 100 yl rabbit antiserum against 
inhi bitor I; (7) 100 ~11 rabbit antiserum against inhibitor II. 
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Inhibitors I and II were immunologically closely 
related. In immunodiffusion, the antiserum raised 
against either of the inhibitors precipitated both 
inhibitor I and inhibitor II. One precipitation arch 
was also formed from human serum, and the precip- 
itate arches from serum, inhibitor I and inhibitor II 
showed ‘reaction of identity’. 
In fig.4 results of an immunoelectrophoresis are 
presented. The precipitate arch of inhibitor II is 
located in the cyi- and that of inhibitor I in &a-region. 
The correspond~g arches were also formed from 
human serum, but no other serum proteins were 
precipitated. 
Identification of the purified inhibitors with the 
known proteinase inhibitors and proteins of human 
serum was attempted by double radial immunodif- 
fusion against those 15 specific antisera given in 
section 2. No one of those antisera precipitated any 
material in inhibitor preparations I and II. In addi- 
tion, the purified inhibitors did not crossreact with 
the antiserum to the epidermal thiol proteinase 
inhibitor, and vice versa, the antisera against the 
serum inhibitors did not precipitate the epiderm~ 
inhibitor. 
4. Discussion 
The simple purification procedure described above 
yielded two proteins having similar immunological 
properties and i~ibiting capacities against thiol 
proteinases. However, they have marked differences 
in their molecular sizes and charges: inhibitor II is 
about twice as large as inhibitor I and has a more 
negative charge and higher electrophoretic mobility 
than inhibitor I. An explanation to these differences 
may be that inhibitor II is a dimer of inhibitor I, or 
inhibitor I is a cleavage product of inhibitor II. 
Inhibitor I seems to be the major form of thiol pro- 
teinase inhibitor in fresh human serum (cf. fig.2,4) 
and is probably identical with the era-thiol proteinase 
inhibitor in [4]. 
The poor inhibition of cathepsin B by the serum 
thiol proteinase inhibitors makes it difficult to 
schedule their physiological function. Probably the 
enzyme affected by them is not cathepsin B, but 
may be one of the other known thiol proteinases of 
human tissues, e.g., cathepsin C [I 11, H 112,131, L 
I12,14I. or collagenolytic cathepsin ]I 51. 
These data suggest hat the human serum thiol 
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proteinase inhibitors are not identical with other 
proteinase inhibitors of serum or with the epidermal 
thiol proteinase inhibitor. The availability of specific 
antiserum makes it possible to quantitate the total 
amount of the inhibitors by simple radial immuno- 
diffusion, or both of them separately by quantitative 
crossed immunoelectrophoresis. 
Recently, a thiol proteinase inhibitor has 
been purified from human serum [ 161. The ~yi - and 
cu2-proteins were not separated and the inhibitor is 
called ‘or-thioi proteinase inhibitor’~ Our results are 
in good agreement. 
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